ABSTRACT
Lifestyle factors remain the bedrock of atherosclerotic cardiovascular disease (ASCVD) prevention. Statins remain the first-line therapy for primary and secondary prevention of ASCVD. Physicians are encouraged to discuss the risks and benefits of statins with patients before beginning therapy. Nonstatins and proprotein convertase subtilisin-kexin type 9 inhibitors are recommended for secondary prevention in patients with clinical ASCVD. For patients at intermediate risk of ASCVD, new risk-enhancing factors, including chronic inflammatory conditions and ethnicity, should be considered to better risk stratify these patients.
Footnotes
Dr. Cho reported research trial support from Amgen, Novartis, and Esperion and consulting/advisory fees from Amgen, Esperion, and AstraZeneca.
This article is based on Dr. Cho’s presentation at the Sones/Favaloro Scientific Program, “Multidisciplinary Management of Acute and Chronic Conditions: Yielding Exceptional Outcomes,” held in Cleveland, OH, November 8, 2019. The article was drafted by Cleveland Clinic Journal of Medicine and was then reviewed, revised, and approved by Dr. Cho.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
- Leslie Cho, MD⇑
- Correspondence:
Leslie Cho, MD, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, JB1, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195; chol{at}ccf.org
ABSTRACT
Lifestyle factors remain the bedrock of atherosclerotic cardiovascular disease (ASCVD) prevention. Statins remain the first-line therapy for primary and secondary prevention of ASCVD. Physicians are encouraged to discuss the risks and benefits of statins with patients before beginning therapy. Nonstatins and proprotein convertase subtilisin-kexin type 9 inhibitors are recommended for secondary prevention in patients with clinical ASCVD. For patients at intermediate risk of ASCVD, new risk-enhancing factors, including chronic inflammatory conditions and ethnicity, should be considered to better risk stratify these patients.
Footnotes
Dr. Cho reported research trial support from Amgen, Novartis, and Esperion and consulting/advisory fees from Amgen, Esperion, and AstraZeneca.
This article is based on Dr. Cho’s presentation at the Sones/Favaloro Scientific Program, “Multidisciplinary Management of Acute and Chronic Conditions: Yielding Exceptional Outcomes,” held in Cleveland, OH, November 8, 2019. The article was drafted by Cleveland Clinic Journal of Medicine and was then reviewed, revised, and approved by Dr. Cho.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.